Los Angeles Capital Management LLC Purchases 7,613 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Los Angeles Capital Management LLC boosted its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 45.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,334 shares of the company’s stock after purchasing an additional 7,613 shares during the period. Los Angeles Capital Management LLC’s holdings in Rhythm Pharmaceuticals were worth $2,721,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in RYTM. EverSource Wealth Advisors LLC grew its holdings in Rhythm Pharmaceuticals by 303.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after purchasing an additional 141 shares during the period. Optiver Holding B.V. increased its stake in Rhythm Pharmaceuticals by 65.2% in the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after purchasing an additional 144 shares during the period. SBI Securities Co. Ltd. increased its stake in Rhythm Pharmaceuticals by 73.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after purchasing an additional 145 shares during the period. Finally, GAMMA Investing LLC increased its stake in Rhythm Pharmaceuticals by 48.6% in the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after purchasing an additional 118 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RYTM. Wells Fargo & Company upped their price target on shares of Rhythm Pharmaceuticals from $143.00 to $144.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Citigroup restated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Royal Bank Of Canada raised their target price on shares of Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $131.81.

Rhythm Pharmaceuticals Stock Performance

Shares of NASDAQ:RYTM opened at $87.86 on Wednesday. The firm has a market cap of $6.02 billion, a PE ratio of -28.07 and a beta of 1.91. The firm’s 50 day simple moving average is $87.77 and its 200-day simple moving average is $96.59. Rhythm Pharmaceuticals, Inc. has a one year low of $60.70 and a one year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.03. The business had revenue of $60.11 million for the quarter, compared to analyst estimates of $55.78 million. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. The company’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same period last year, the company posted ($0.81) earnings per share. Equities research analysts predict that Rhythm Pharmaceuticals, Inc. will post -3.07 EPS for the current fiscal year.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.